Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Bristol-Myers Signs Deals With Biotechs
by Ann M. Thayer
June 2, 2014
| A version of this story appeared in
Volume 92, Issue 22
Bristol-Myers Squibb will pay $50 million up front to access CytomX Therapeutics’ Probody technology for up to four cancer targets. BMS will also provide research funding and up to $298 million in milestone payments for each collaboration target. Probodies are monoclonal antibodies that can be selectively activated at the cancer site to spare healthy tissue. In another deal, BMS and Incyte will conduct initial clinical trials on a cancer-fighting combination of BMS’s nivolumab, a PD-1 immune checkpoint inhibitor, and Incyte’s oral indoleamine dioxygenase-1 inhibitor.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter